Abstract
Early phase 2 tuberculosis (TB) trials are conducted to characterize the early bactericidal activity (EBA) of anti-TB drugs. The EBA of anti-TB drugs has conventionally been calculated as the rate of decline in colony forming unit (CFU) count during the first 14 days of treatment. The measurement of CFU count, however, is expensive and prone to contamination. Alternatively to CFU count, time to positivity (TTP), which is a potential biomarker for long-term efficacy of anti-TB drugs, can be used to characterize EBA. The current Bayesian nonlinear mixed-effects (NLME) regression model for TTP data, however, lacks robustness to gross outliers that often are present in the data. The conventional way of handling such outliers involves their identification by visual inspection and subsequent exclusion from the analysis. However, this process can be questioned because of its subjective nature. For this reason, we fitted robust versions of the Bayesian nonlinear mixed-effects regression model to a wide range of TTP datasets. The performance of the explored models was assessed through model comparison statistics and a simulation study. We conclude that fitting a robust model to TTP data obviates the need for explicit identification and ...Continue Reading
References
Jul 15, 2006·The Journal of Antimicrobial Chemotherapy·D A Mitchison
Feb 28, 2009·The Lancet Infectious Diseases·Robert S WallisAlimuddin Zumla
Jul 25, 2009·Statistics in Medicine·David LunnNicky Best
May 26, 2010·Antimicrobial Agents and Chemotherapy·Andreas H DiaconMelvin K Spigelman
Oct 12, 2010·Journal of Clinical Microbiology·Marc WeinerA Willem Sturm
Aug 20, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A H DiaconP R Donald
Mar 21, 2012·Antimicrobial Agents and Chemotherapy·Andreas H DiaconMelvin K Spigelman
May 11, 2012·Journal of Clinical Microbiology·Derek J SloanGeraint R Davies
Jul 26, 2012·Lancet·Andreas H DiaconMelvin K Spigelman
Nov 28, 2012·Antimicrobial Agents and Chemotherapy·Emmanuel ChigutsaMats O Karlsson
Mar 6, 2013·Antimicrobial Agents and Chemotherapy·Andreas H DiaconCarl M Mendel
Oct 10, 2013·Pharmaceutical Statistics·Rolando De la Cruz
Oct 16, 2013·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·C M BarkJ L Johnson
Oct 17, 2014·Journal of Biopharmaceutical Statistics·Divan Aristo Burger, Robert Schall
Jan 27, 2015·American Journal of Respiratory and Critical Care Medicine·Andreas H DiaconCarl M Mendel
Mar 22, 2015·Lancet·Rodney DawsonCarl M Mendel
Feb 6, 2016·BMC Medicine·Patrick P J PhillipsStephen H Gillespie
Sep 30, 2017·The Journal of Antimicrobial Chemotherapy·Elin M Svensson, Mats O Karlsson
Nov 7, 2017·Statistics in Medicine·Divan Aristo Burger, Robert Schall